Pfizer Xanax 2mg

Clinical Monograph: Xanax Pfizer 2 mg (Alprazolam Immediate-Release)

1. Classification and Chemical Overview

Alprazolam is a short-acting, high-potency triazolo-analogue of the 1,4-benzodiazepine class. Chemically designated as 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine, its molecular structure incorporates a fused triazole ring that enhances receptor binding affinity compared to standard benzodiazepines. Under the Anatomical Therapeutic Chemical (ATC) system, alprazolam is indexed under N05BA12.

• Product Context: Xanax is a globally recognized brand-name formulation originally developed by Pfizer. The 2 mg strength typically represents a multi-scored tablet (often bar-shaped, designed to be broken into smaller fractions) formulated for immediate release. Because of its high potency and wide brand recognition, this specific presentation is heavily targeted by illicit counterfeiters; unregulated online or street procurement carries extreme risks of dangerous synthetic adulterants (such as illicit fentanyl) and variable dosing.

• Controlled Status: Classified as a Controlled Substance (Schedule IV under the US CSA; Schedule 4 / Prescription Only Medicine internationally) due to its high physical dependence liability, rapid onset, and significant potential for recreational misuse and abuse.

2. Mechanism of Action and Pharmacodynamics

Alprazolam functions as a positive allosteric modulator at central nervous system FRENTEA​ receptor complexes:

• High-Affinity Receptor Modulation: Binds selectively to benzodiazepine site interfaces (α1​, α2​, α3​, or α5​ subunits paired with γ2​) on postsynaptic ionotropic FRENTEA​ receptors across the limbic system, cortex, and thalamus.

• Chloride Conductance Enhancement: Facilitates GABA-mediated opening of chloride channels, generating inward chloride currents that hyperpolarize neuronal membranes and suppress electrical excitability.

• Rapid Anxiolysis: High lipophilicity enables fast crossing of the blood-brain barrier, resulting in a rapid onset of peak clinical effects to abort acute panic or anxiety surges.

3. Approved Clinical Indications and Dosing Scope

Licensing and standard clinical uses for alprazolam include:

• Panic Disorder: Treatment of panic disorder with or without agoraphobia.

• Generalized Anxiety Disorder (GAD): Short-term management of severe anxiety states.

Dosing & Administration Regimen:

• Unit Strength Scope: The 2 mg tablet is a very high unit strength reserved for established maintenance therapy in patients with high tolerance under close clinical supervision. It is never utilized as an initial starting dose (which typically begins at 0.25 mg to 0.5 mg).

• Administration & Scoring: Tablets feature score lines permitting division, but must be taken strictly as prescribed.

• Duration Restrictions: Use should be restricted to the shortest effective period with mandatory, slow dose tapering upon discontinuation to mitigate severe withdrawal reactions.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Rapidly and completely absorbed following oral administration, with peak plasma concentrations (Cmax​) attained swiftly within 1 to 2 hours (Tmax​).

• Distribution: Plasma protein binding is approximately 80% (primarily to serum albumin). Distributes rapidly across the blood-brain barrier, placental barrier, and into breast milk.

• Biotransformation: Extensively metabolized in the liver via hepatic Cytochrome P450 enzymes (predominantly CYP3A4):

  • Hydroxylated to $\alpha$-hydroxyalprazolam (retains ~66% of parent potency) and 4-hydroxyalprazolam.

  • Metabolites undergo subsequent glucuronidation prior to renal excretion.

• Elimination: Excreted primarily via the urine as glucuronide conjugates and unchanged drug (~20%). Mean elimination half-life (t1/2​) ranges from 11 to 16 hours in healthy adults.

5. Physiological Effects and Adverse Event Spectrum

Alprazolam suppresses central nervous system arousal, motor coordination, cognitive speed, and emotional reactivity.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Sedation, somnolence, fatigue, impaired coordination, ataxia, memory impairment, speech dysfluency.

• Common ($\ge 1/100$ to $<1/10$): Lightheadedness, cognitive dysfunction, irritability, constipation, dry mouth, changes in weight/appetite, blurred vision.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Paradoxical disinhibition, rage, hallucinations, muscle weakness, confusion, altered libido.

• Rare / Severe (<1/1,000): Respiratory depression, severe withdrawal syndrome/seizures, hepatic failure, Stevens-Johnson syndrome.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindicaciones

• Known hypersensitivity to alprazolam or other benzodiazepines.

• Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole).

• Severe acute respiratory insufficiency, sleep apnea, or myasthenia gravis.

• Acute narrow-angle glaucoma.

Key Drug Interactions

• Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir): Significantly inhibit alprazolam metabolism, escalating plasma levels up to several-fold and provoking severe toxicity, prolonged sedation, and respiratory compromise.

• Opioids, Alcohol, & CNS Depressants: Co-administration causes synergistic central nervous system and respiratory depression, dramatically increasing the risk of coma and fatal overdose.

• CYP3A4 Inducers (e.g., Carbamazepine, St. John’s Wort, Rifampicin): Accelerate clearance, markedly reducing therapeutic plasma levels.

Clinical Precautions and Monitoring

• Boxed Warning (Concomitant Opioid Use & Addiction/Dependence): Combined use with opioids increases risk of severe respiratory depression, coma, and death. Alprazolam carries a high abuse liability and physical dependence potential; rapid withdrawal following continuous exposure causes life-threatening grand mal seizures, psychosis, and delirium tremens.